Safety and efficacy of S 38093 versus placebo in patients with Alzheimer's Disease. An international, multi-centre, randomised, double-blind, placebo-controlled phase IIa study.

Trial Profile

Safety and efficacy of S 38093 versus placebo in patients with Alzheimer's Disease. An international, multi-centre, randomised, double-blind, placebo-controlled phase IIa study.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2012

At a glance

  • Drugs S 38093 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 28 Apr 2012 Additional primary endpoints identified as reported by European Clinical Trials Database.
    • 28 Apr 2012 Additional trial locations added as reported by European Clinical Trials Database.
    • 28 Apr 2012 Actual end date 13 Sep 2010 added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top